XML 68 R55.htm IDEA: XBRL DOCUMENT
v3.20.2

License and Collaboration Agreements - Additional Information (Details) - USD ($) | 1 Months Ended | 3 Months Ended | 9 Months Ended
--- | --- | --- | ---
Nov. 30, 2019 | Dec. 31, 2019 | Sep. 30, 2020
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |
Payments on license agreement milestone in acquired in process research and development expenses |  |  | $ 10,000,000.0
Agenus Agreement |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |
Upfront fee | $ 10,000,000.0 |  |
Maximum amount payable upon achieving certain clinical development and regulatory milestones | 115,000,000.0 |  |
Maximum amount payable upon achieving certain commercial milestones | $ 85,000,000.0 |  |
License agreement milestone in acquired in-process research and development expenses |  | $ 10,000,000.0 |
Agenus Agreement | After First Commercial Sale of Licensed Product |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |
License agreement expiration term | 15 years |  |
Maximum | Agenus Agreement |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |
Royalty ranging on net sales of licensed products | 20.00% |  |
Minimum | Agenus Agreement |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |
Royalty ranging on net sales of licensed products | 14.00% |  |
Allergan/AbbVie | License Agreement |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |
Milestone payments received for licensing agreement |  |  | 25,000,000.0
Allergan/AbbVie | License Agreement | Maximum |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |
License agreement additional milestone payments eligible to receive |  |  | $ 200,000,000.0

X
- Definition Contract with customer additional milestone payment eligible to receive. + References No definition available. + Details
Name: | urgn_ContractWithCustomerAdditionalMilestonePaymentEligibleToReceive
Namespace Prefix: | urgn_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition License agreement expiration term. + References No definition available. + Details
Name: | urgn_LicenseAgreementExpirationTerm
Namespace Prefix: | urgn_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition License agreement milestone in acquired in-process research and development expenses. + References No definition available. + Details
Name: | urgn_LicenseAgreementMilestoneInAcquiredInProcessResearchAndDevelopmentExpenses
Namespace Prefix: | urgn_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Maximum amount payable upon achieving certain clinical development and regulatory milestones. + References No definition available. + Details
Name: | urgn_MaximumAmountPayableUponAchievingCertainClinicalDevelopmentAndRegulatoryMilestones
Namespace Prefix: | urgn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Maximum amount payable upon achieving certain commercial milestones. + References No definition available. + Details
Name: | urgn_MaximumAmountPayableUponAchievingCertainCommercialMilestones
Namespace Prefix: | urgn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Milestone payment received for licensing agreement. + References No definition available. + Details
Name: | urgn_MilestonePaymentsReceivedForLicensingAgreement
Namespace Prefix: | urgn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Payment on license agreement milestone in acquired in process research and development expenses. + References No definition available. + Details
Name: | urgn_PaymentOnLicenseAgreementMilestoneInAcquiredInProcessResearchAndDevelopmentExpenses
Namespace Prefix: | urgn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Royalty ranging on net sales of licensed products. + References No definition available. + Details
Name: | urgn_RoyaltyRangingOnNetSalesOfLicensedProducts
Namespace Prefix: | urgn_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Upfront fee. + References No definition available. + Details
Name: | urgn_UpfrontFee
Namespace Prefix: | urgn_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=urgn_AfterFirstCommercialSaleOfLicensedProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=urgn_AllerganPharmaceuticalsInternationalLimitedAndAbbVieIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=urgn_LicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |